right mix of assets to excel in cell therapies, page-51

yep, this topic had been discussed in the past.

http://hotcopper.com.au/post_single.asp?fid=1&tid=1475159&msgid=8398636

Also related media coverage for the event
http://cancerology.blogspot.com/2011/06/asco-2011-abagovomab-failed-in-ovarian.html.

it was the only known competitor to CVac but now in the history. It's not a good news for patients, but not a bad news for Prima's investors either.

So yes, if all plan goes well, Cvac could be the first maintenance type treatment for ovarian cancers that using this advanced technology in the world.

And yet we are still just targeting 10% of the market. So no need to panic if there's some competitor coming out of the left field.

I also like the company approach towards this matter as well. here is the reply I got from MR back in June when I queried about the competitors issue,

' It is not our policy to talk directly about other companies and this is not seen as a direct competitor. Generally speaking immunotherapies will be the next generation of cancer therapies as you see the trend for lower toxicities and improved quality of life for patients which is a good thing.'

which translated to me that 'we are ok for competition, had budgeted it already, don't worry about it' :-)'

Go Prima!